Quick answer
What does the research record on KPV actually show? KPV is the C-terminal tripeptide of α-MSH. Published cell studies report reduced NF-κB-linked readouts, PepT1-dependent uptake and in vitro antimicrobial effects; mouse colitis studies report reduced inflammatory readouts. Mechanism, receptor dependence and anything beyond those systems remain open. For laboratory research use only.
A guide to a research peptide is most useful when it separates what has been shown from what has only been suggested. KPV is a good example, because its literature is small, mostly preclinical, and easy to over-read. This guide organizes it into evidence tiers: findings reported in cell lines, findings reported in mice, ideas that come from the parent hormone, and open questions. It then gives a short checklist for reading any new KPV paper. For laboratory research use only; not for human consumption.
KPV is the tripeptide Lys-Pro-Val. The KPV research vials page lists it as a lyophilized powder, 5 mg and 10 mg vials, ≥98% HPLC purity, with research uses described as melanocortin pathway research, mucosal and gut-inflammation models, and NF-κB signaling studies. Single-topic articles go deeper; the guide points to them at each tier. Entry points are what is KPV, the KPV research overview and understanding amino acid sequences.
Tier 1: What the parent hormone literature provides
α-MSH is a 13-residue melanocortin peptide with documented anti-inflammatory effects in many experimental settings, which are linked to centrally and peripherally expressed melanocortin receptors and to effects on NF-κB, cytokine production and other pathways. A review of α-MSH and related tripeptides records that the C-terminal tripeptide KPV keeps the anti-inflammatory effect of the hormone while lacking its pigmentary action, which is why KPV was proposed as an alternative [1]. A pharmacology review of melanocortin peptides frames receptor activation, especially MC1R and MC3R, as a preclinical strategy to control inflammation and notes the short half-life and lack of selectivity of natural melanocortins as obstacles [8]. This tier is background: it explains why KPV was studied, not what KPV does. See KPV vs α-MSH.
Tier 2: Reported in cultured cells
| Finding | System | Source | Deeper article |
|---|---|---|---|
| Nanomolar KPV inhibited NF-κB and MAP kinase signaling and reduced cytokine secretion | Intestinal epithelial cells, Jurkat T cells | [2] | KPV and NF-κB evidence |
| Uptake of KPV via PepT1 | Intestinal epithelial and immune cells | [2] | KPV and PepT1 uptake background |
| Dose-dependent inhibition of NF-κB, MMP-9, IL-8 and eotaxin, with IκBα stabilization and reduced p65 nuclear translocation | Bronchial epithelial cells | [4] | KPV inflammation research models |
| Reduced S. aureus colony formation and C. albicans viability | Microbial cultures | [5] | KPV antimicrobial background |
| C-terminal fragments killed more than 90% of S. aureus cells in the micromolar range; the N-terminal fragment was ineffective | S. aureus (including methicillin-resistant strains) | [6] | KPV antimicrobial assays guide |
These are the strongest, most mechanistic observations in the KPV record, and they are also the most limited in reach: cell lines, short exposures, defined media.
Tier 3: Reported in mice
Mouse colitis studies report that KPV, given in drinking water, reduced the incidence of DSS- and TNBS-induced colitis and cytokine expression [2], and that it produced earlier recovery, fewer inflammatory infiltrates and lower myeloperoxidase activity in DSS and transfer colitis, with survival of all animals in an MC1R-deficient group [3]. A nanoparticle-in-hydrogel preparation protected mice from DSS colitis at a KPV concentration reported as 12,000-fold lower than free KPV [7]. The models, endpoints and delivery systems are dissected in the articles on murine colitis models and on nanoparticle delivery. This tier is narrow: one species, one organ system, a few research groups.
Tier 4: Open questions
- Mechanism. Studies report different steps in different cells, including reduced reporter activity, IκBα stabilization and reduced p65 nuclear import, with no single sequence established.
- Receptor dependence. Effects persisted in MC1R-deficient mice and in airway cells, but the contribution of receptors in other contexts is unresolved [3, 4].
- Concentration and exposure. Cell work uses nanomolar to micromolar concentrations; animal work uses different delivery formats. Direct comparison is not possible from the abstracts.
- Stability in biological media. Short peptides can be cleaved quickly; intact-peptide measurements are rarely reported in abstracts.
- Combination with other compounds. No cited study tests KPV together with other research peptides; for blends, see KLOW Stack research guide and KLOW Stack product page.
A checklist for reading a KPV paper
| Question | Why it matters |
|---|---|
| Which model: cell line, primary cells, mouse strain? | Effects in one system do not transfer automatically to another |
| What exactly was measured? | A reporter result, a cytokine level and a histology score answer different questions |
| How was the peptide delivered, and in what vehicle? | Free solution, drinking water and nanoparticles are different test articles |
| Was the peptide characterized? | Identity, purity and counterion determine what was actually tested |
| Is there a vehicle control and an inactive-peptide control? | Excludes non-specific effects |
| Were measurements blinded and replicated? | Histology and cell assays are noisy |
| Who produced the data? | Reports from one group need independent confirmation |
Applying this list to the studies above shows how often abstracts leave out the details that decide reproducibility; the full papers should always be consulted.
How the tiers connect, and where the joins are weak
The tiers form a chain of inference: the hormone literature suggests a fragment may carry anti-inflammatory activity; cell studies test that and locate candidate pathways; mouse studies ask whether the effect appears in an organism with a gut barrier, immune cells and a microbiome. Each join is weaker than the pieces it links. Between tiers 1 and 2, the receptor explanation for the hormone does not carry over cleanly to the tripeptide, since KPV effects were reported without the classical receptor in some systems [3, 4]. Between tiers 2 and 3, uptake via PepT1 explains entry in cell lines [2], yet the transporter is absent from normal colon, which is why delivery formats such as nanoparticles in hydrogels were explored [7]. And between the cell and microbe results there is no demonstrated link: the antimicrobial effects were reported in culture only, with membrane effects proposed in bacteria [6].
A reader should regard each join as a separate question. When someone cites KPV in a new context, the useful test is which tier the claim comes from and whether the evidence at that tier actually covers the new context. A claim made in a gut-cell line does not become a claim about airway tissue because both are epithelial, and a claim about colitis in mice does not become a claim about a different organ.
A suggested reading order
- Start with the overview in KPV research overview and the definition in what is KPV to fix the vocabulary.
- Read the sequence and structure article to understand what a tripeptide can and cannot be.
- Read the NF-κB and inflammation-model articles for the cell-level evidence.
- Read the PepT1 article for the uptake question and assay design.
- Read the colitis and nanoparticle articles for the mouse evidence.
- Read the antimicrobial assay guide for the in vitro microbial work.
- Finish with the handling and chemistry articles when preparing to use the reagent in the lab.
This order moves from vocabulary to mechanism to organism to practice, and it keeps the most speculative material for the end of the reading list. A reader short on time can stop after the third item and still have the core of the cell-level literature.
Using the compound in a lab: practical pointers
If KPV is used as a reagent in experiments, the practical pointers are modest. Confirm identity and purity from the batch documentation, where published, on the COA page; see how to read a COA and third-party testing explained for how to read it. Handle the vial as the product page states, with refrigerated or frozen storage and protection from heat, moisture and light, following the steps in the article on KPV lab handling. Calculate concentrations from formulas, concentration equals mass divided by volume and molar concentration equals that divided by about 342.4 g/mol, and use the reconstitution calculator for lot-specific numbers. Keep the units explicit in every record. The single-peptide and blend options are listed in the research catalog; for the comparison of KPV with another research tripeptide, see GHK-Cu vs KPV.
Summary of what can and cannot be said
Can be said: KPV is the C-terminal tripeptide of α-MSH; in published cell studies it reduced NF-κB-linked readouts and cytokine secretion in epithelial cells, uses PepT1 for uptake in gut-cell models and reduced survival of some microbes in vitro; and in published mouse colitis studies it was associated with reduced inflammatory readouts. Cannot be said: that any of this extends beyond those systems, that a mechanism is settled, or that results from cultured cells predict whole-tissue outcomes. The sensible use of this literature is as a source of testable questions.
Frequently asked questions
What is KPV?
The tripeptide Lys-Pro-Val, which corresponds to residues 11-13 at the C-terminal end of α-MSH.
What are the main research areas for KPV?
Melanocortin pathway research, gut-inflammation models and NF-κB signaling studies, as described on the product page and in the published literature.
What has been reported in cultured cells?
Reduced NF-κB and MAP kinase signaling, lower cytokine secretion, PepT1-dependent uptake and reduced survival of some microbes in vitro.
What has been reported in mice?
Reduced inflammatory readouts in DSS, TNBS and transfer colitis models, including with nanoparticle-based delivery.
Does KPV require a melanocortin receptor?
Effects persisted in MC1R-deficient mice and in airway cells, so receptor dependence is at best partial in the systems tested.
Is the mechanism settled?
No. Different studies report different steps in different cells.
Are there studies of KPV in combination with other peptides?
None are cited in this guide.
How should I read a KPV paper?
Check the model, the measurement, the delivery format, the peptide characterization, controls, blinding and independence of the data.
What do I need to know to calculate a stock concentration?
Peptide mass divided by diluent volume gives concentration; divide by about 342.4 g/mol for molar units.
Where do I find product facts?
On the KPV product page: sizes, purity, supplied form and storage.
Related reading: KPV vs Other Peptides: Choosing Research Comparators, KPV in Tissue Injury and Repair Models: Evidence Map, KPV in Animal Studies: Published Parameters and Math.
References
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases. Endocrine Reviews. 2008;29(5):581-602. doi:10.1210/er.2007-0027
- Dalmasso G, Charrier–Hisamuddin L, Thu Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
- Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. doi:10.1002/ibd.20334
- Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2). PMID: 22837805
- Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of α-MSH peptides. Journal of Leukocyte Biology. 2000;67(2):233-239. doi:10.1002/jlb.67.2.233
- Singh M, Mukhopadhyay K. C-Terminal Amino Acids of Alpha-Melanocyte-Stimulating Hormone Are Requisite for Its Antibacterial Activity against Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(5):1920-1929. doi:10.1128/AAC.00957-10
- Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. Drug-Loaded Nanoparticles Targeted to the Colon With Polysaccharide Hydrogel Reduce Colitis in a Mouse Model. Gastroenterology. 2010;138(3):843-853.e2. doi:10.1053/j.gastro.2009.11.003
- Catania A, Gatti S, Colombo G, Lipton JM. Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation. Pharmacological Reviews. 2004;56(1):1-29. doi:10.1124/pr.56.1.1
